Financing included participation by healthcare-dedicated investors alongsideexisting shareholdersCHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) ...

Joining me on today's call from Vir Biotechnology, Inc., are Dr. Marianne De Backer, our Chief Executive Officer, Dr. Mark D.

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated ...

Konik Capital Partners LLC, a division of T.R. Winston & Company, is acting as the sole book-running manager for the offering. MAIA intends to use the net proceeds from the offering to conduct ...

Anbio Biotechnology continues pivoting toward better profitability metrics, prioritized high-margin orders over sales volume. Read more on NNNN stock here.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, February 25, 2026. Let’s ...

Vir Biotechnology, Inc. ( VIR) Q4 2025 Earnings Call February 23, 2026 5:30 PM EST ...

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evad ...

26 Therapeutics is a preclinical-stage biotechnology company developing small-molecule therapies for dry eye disease and other meibomian gland disorders. The company's lead program is a topical, ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA ...